X

Trial Profile

An Open Label, Intra-Subject Dose Escalation Study of CCX140-B in Subjects With Primary Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic Syndrome

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 12 Feb 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ilacirnon (Primary)
Indications Focal segmental glomerulosclerosis
Focus Registrational; Therapeutic Use
Acronyms LUMINA2
Sponsors ChemoCentryx

Most Recent Events

10 Jan 2024 Status changed from recruiting to discontinued. (Program not advancing)
10 Oct 2020 This trial has been discontinued in Poland (Date of the global end of the trial: 24 June 2020).
10 Mar 2020 According to an ChemoCentryx media release, data from this study is expected by year-end 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com